Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 484919, 7 pages
http://dx.doi.org/10.1155/2012/484919
Research Article

Genetics of Myasthenia Gravis: A Case-Control Association Study in the Hellenic Population

1Laboratory of Molecular Biology and Immunology, Department of Pharmacy, School of Health Sciences, University of Patras, Rion, 26504 Patras, Greece
2Department of Biochemistry, Hellenic Pasteur Institute, 127 Vassilissis Sofias Avenue, 11521 Athens, Greece

Received 15 June 2012; Accepted 16 August 2012

Academic Editor: Timothy B. Niewold

Copyright © 2012 Zoi Zagoriti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Kalamida, K. Poulas, V. Avramopoulou et al., “Muscle and neuronal nicotinic acetylcholine receptors: structure, function and pathogenicity,” FEBS Journal, vol. 274, no. 15, pp. 3799–3845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Hoch, J. Mcconville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent, “Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies,” Nature Medicine, vol. 7, no. 3, pp. 365–368, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Zhang, J. S. Tzartos, M. Belimezi, S. Ragheb, B. Bealmear, R. A. Lewis et al., “Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis,” Archives of Neurology, vol. 69, no. 4, pp. 445–451, 2012. View at Google Scholar
  4. A. S. Carr, C. R. Cardwell, P. O. McCarron, and J. McConville, “A systematic review of population based epidemiological studies in Myasthenia Gravis,” BMC Neurology, vol. 10, article 46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Drachman, “Myasthenia gravis,” in The Autoimmune Diseases, N. Rose and I. Mackay, Eds., Chapter 31, pp. 637–662, Academic Press, 3rd edition, 1999. View at Google Scholar
  6. T. Namba, N. G. Brunner, S. B. Brown, M. Muguruma, and D. Grob, “Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families.,” Archives of Neurology, vol. 25, no. 1, pp. 49–60, 1971. View at Google Scholar · View at Scopus
  7. R. Pirskanen, “Genetic aspects in Myasthenia gravis. A family study of 264 Finnish patients,” Acta Neurologica Scandinavica, vol. 56, no. 5, pp. 365–388, 1977. View at Google Scholar · View at Scopus
  8. R. A. Marrie, D. J. Sahlas, and G. M. Bray, “Familial autoimmune myastenia gravis: four patients involving three generations,” Canadian Journal of Neurological Sciences, vol. 27, no. 4, pp. 307–310, 2000. View at Google Scholar
  9. D. P. Bogdanos, D. S. Smyk, E. I. Rigopoulou, M. G. Mytilinaiou, M. A. Heneghan, C. Selmi et al., “Twin studies in autoimmune disease: genetics, gender and environment,” Journal of Autoimmunity, vol. 38, no. 2-3, pp. J156–J169, 2012. View at Google Scholar
  10. P. B. Christensen, T. S. Jensen, I. Tsiropoulos, T. Sørensen, M. Kjaer, E. Højer-Pedersen et al., “Associated autoimmune diseases in myasthenia gravis. A population-based study,” Acta Neurologica Scandinavica, vol. 91, no. 3, pp. 192–195, 1995. View at Google Scholar
  11. M. Giraud, G. Beaurain, A. M. Yamamoto et al., “Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies,” Neurology, vol. 57, no. 9, pp. 1555–1560, 2001. View at Google Scholar · View at Scopus
  12. C. Vandiedonck, G. Beaurain, M. Giraud et al., “Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthemia gravis and thymus hyperplasia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 43, pp. 15464–15469, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Giraud, C. Vandiedonck, and H. J. Garchon, “Genetic factors in autoimmune myasthenia gravis,” Annals of the New York Academy of Sciences, vol. 1132, pp. 180–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. V. Kozyrev and M. E. Alarcon-Riquelme, “The genetics and biology of Irf5-mediated signaling in lupus,” Autoimmunity, vol. 40, no. 8, pp. 591–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. D. S. C. Graham, H. Manku, S. Wagner et al., “Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation,” Human Molecular Genetics, vol. 16, no. 6, pp. 579–591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. E. Mancl, G. Hu, N. Sangster-Guity et al., “Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms: multiple isoforms with distinct cell type-specific expression, localization, regulation, and function,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 21078–21090, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. I. E. Wartz, K. M. O'Rourke, H. Zhou et al., “De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling,” Nature, vol. 430, no. 7000, pp. 694–699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Vereecke, R. Beyaert, and G. van Loo, “The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology,” Trends in Immunology, vol. 30, no. 8, pp. 383–391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. Musone, K. E. Taylor, T. T. Lu et al., “Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus,” Nature Genetics, vol. 40, no. 9, pp. 1062–1064, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. W. Rowbottom, M. A. Lepper, R. J. Garland, C. V. Cox, and E. G. Corley, “Interleukin-10-induced CD8 cell proliferation,” Immunology, vol. 98, no. 1, pp. 80–89, 1999. View at Google Scholar
  21. K. W. Moore, R. D. W. Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. G. X. Zhang, B. G. Xiao, L. Y. Yu, P. H. Van der Meide, and H. Link, “Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR,” Journal of Neuroimmunology, vol. 113, no. 1, pp. 10–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. D. M. Turner, D. M. Williams, D. Sankaran, M. Lazarus, P. J. Sinnott, and I. V. Hutchinson, “An investigation of polymorphism in the interleukin-10 gene promoter,” European Journal of Immunogenetics, vol. 24, no. 1, pp. 1–8, 1997. View at Google Scholar · View at Scopus
  24. P. K. Gregersen and L. M. Olsson, “Recent advances in the genetics of autoimmune disease,” Annual Review of Immunology, vol. 27, pp. 363–391, 2009. View at Google Scholar
  25. R. R. Graham, C. Kyogoku, S. Sigurdsson, I. A. Vlasova, L. R. Davies, E. C. Baechler et al., “Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 16, pp. 6758–6763, 2007. View at Google Scholar
  26. B. Z. Levi, S. Hashmueli, M. Gleit-Kielmanowicz, A. Azriel, and D. Meraro, “ICSBP/IRF-8 transactivation: a tale of protein-protein interaction,” Journal of Interferon and Cytokine Research, vol. 22, no. 1, pp. 153–160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Rechsteiner and S. W. Rogers, “PEST sequences and regulation by proteolysis,” Trends in Biochemical Sciences, vol. 21, no. 7, pp. 267–271, 1996. View at Google Scholar
  28. R. M. Plenge, C. Cotsapas, L. Davies, A. L. Price, P. I. de Bakker, J. Maller et al., “Two independent alleles at 6q23 associated with risk of rheumatoid arthritis,” Nature Genetics, vol. 39, no. 12, pp. 1477–1482, 2007. View at Google Scholar
  29. I. R. Mackay, “Clustering and commonalities among autoimmune diseases,” Journal of Autoimmunity, vol. 33, no. 3-4, pp. 170–177, 2009. View at Google Scholar
  30. W. Y. Wang, B. J. Barratt, D. G. Clayton, and J. A. Todd, “Genome-wide association studies: theoretical and practical concerns,” Nature Reviews Genetics, vol. 6, no. 2, pp. 109–118, 2005. View at Google Scholar
  31. J. D. Rioux and A. K. Abbas, “Paths to understanding the genetic basis of autoimmune disease,” Nature, vol. 435, no. 7042, pp. 584–589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. E. H. Alseth, H. L. Nakkestad, J. Aarseth, N. E. Gilhus, and G. O. Skeie, “Interleukin-10 promoter polymorphisms in myasthenia gravis,” Journal of Neuroimmunology, vol. 210, no. 1-2, pp. 63–66, 2009. View at Publisher · View at Google Scholar · View at Scopus